Skin Therapy Letter HOME
Written for dermatologists by dermatologists. Indexed by the US National Library of Medicine.
Skin Information
NETWORK
Skin Therapy Letter About STL Subscribe Today SkinCareGuide Network Site Map
CUSTOM DERMATOLOGY SEARCH:
Loading


Drug Treatments for Skin Disease Introduced in 2004

Drug Class

Generic/Trade
Company Names

Indication

Approving
Regulatory Agency

Antiacne Agent

Clindamycin Foam 1%
Evoclin®
Connetics

Approved for topical application in the treatment of acne vulgaris

US FDA

Antibacterial
Agent

Cefdinir Oral Suspension
Omnicef®
Abbott Laboratories

A new 250mg/5ml dosing option approved for use in pediatric patients 6 months to 12 years of age. This more concentrated form allows parents to administer fewer teaspoons/ dose to their children.

US FDA

Clindamycin
Evoclin® Foam 1%

Connetics

Approved for the treatment of mild-tomoderate acne vulgaris. Evoclin® was formerly referred to as Actiza™.

US FDA

Antihistamine

Desloratadine Syrup
CLARINEX®
Schering-Plough

Approved for the relief of symptoms associated with seasonal allergic rhinitis
in children >2 years of age, and perennial allergic rhinitis and chronic idiopathic urticaria, or hives of unknown cause in children as young as 6 months of age.

US FDA

Antipruritic Agent

Cetirizine HCl
Zyrtec®
Pfizer/UCB Pharma

A new chewable formulation approved for the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria in
children >2 years of age.

US FDA

Antipsoriatic Agent

Alefacept
Amevive®
Biogen Idec

Approved for the treatment of adult patients with moderate-to-severe chronic plaque
psoriasis who are candidates for systemic therapy or phototherapy.

Israeli Ministry of
Health
Therapeutic Goods
Administration—
Australia
TPP Canada

Efalizumab
Raptiva®
Serono

Approved for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis.

Swissmedic
CHMP Europe

Etanercept
Enbrel®
Amgen/Wyeth
Pharmaceuticals

Approved for the treatment of moderate-tosevere
plaque psoriasis who failed to respond
to, or have a contraindication to, or are
intolerant of other systemic therapy.

US FDA
CHMP Europe

Dermal Filler

Hyaluronic Acid Filler
Hyalite™
Mentor

Approved for soft tissue augmentation in the correction of wrinkles and folds and for lip enhancement.

CHMP Europe

Hyaluronic Acid Filler
RESTYLANE®
Medicis

Approved for the correction of moderate-tosevere facial wrinkles and folds.

US FDA

Hylan-B Gel
Hylaform
Inamed/Genzyme

Approved for injection into the mid-to-deep dermis for correction of moderate-to-severe facial wrinkles and folds.

US FDA

Injectable Poly-L-Lactic Acid
Sculptra
Dermik Laboratories

Approved for the correction of lipoatrophy in people with HIV infection.

US FDA

Enzyme Replacement
Therapy

Agalsidase Alfa
Replegal™
Transkaryotic Therapies

Approved for the treatment of Fabry disease under its Notice of Compliance with Conditions Policy, under which Transkaryotic Therapies can market this product while conducting post-marketing studies

TPP Canada

Immunomodulatory
Agent

Imiquimod Cream 5%
Aldara®
3M Pharmaceuticals

Approved for clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults.

US FDA
TPP Canada

Imiquimod Cream 5%
Aldara®
3M Pharmaceuticals

Approved for the treatment of biopsyconfirmed, primary superficial basal cell carcinoma in adults with normal immune systems.

US FDA
TPP Canada

Medical Device

Clinical Phototherapy
System

ClearTouch™ Light Unit
Assembly

Radiancy

Approved for the treatment of pustular inflammatory acne.

US FDA

Ultrasonic Skin
Permeation Device

SonoPrep®
Sontra Medical

Approved for use with topical lidocaine.

US FDA

Monoclonal Antibody

SGN-30

Seattle Genetics

Granted Orphan Drug Designation for the treatment of T-cell lymphomas.

US FDA

Neurotoxin

Botulinum Toxin – Type A
BOTOX®
Allergan

Additional indication approved for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents.

US FDA

Oncologic Agent

MDX-010

Medarex

Granted Orphan Drug Designation for the treatment of high-risk Stage II, Stage III, and Stage IV melanoma.

US FDA

Psoriatic Arthritis
Agent

Leflunomide
Arava®
Aventis

A new indication approved for the treatment of adult patients with active psoriatic arthritis.

CHMP Europe

Etanercept
Enbrel®
Amgen/Wyeth
Pharmaceuticals

Approved for the treatment of psoriatic arthritis.

 

Etanercept
Enbrel®
Amgen/Wyeth
Pharmaceuticals

New dosing formula approved for the treatment of psoriatic arthritis and moderateto- severe plaque psoriasis – a prefilled syringe that will eliminate the need to mix the drug prior to injecting and will allow most patients receiving this drug to take only one injection/week instead of the two 25mg injections currently used weekly by patients.

US FDA

Infliximab
REMICADE®
Schering-Plough/Centocor

Approved for use in combination with methotrexate for the treatment of active and progressive psoriatic arthritis in patients who have responded inadequately to diseasemodifying antirheumatic drugs.

CHMP Europe


  1. Table of Contents
  2. Mycophenolate Mofetil: A Dermatologic Perspective
  3. Drug Treatments for Skin Disease Introduced in 2004
  4. Twelve Technical Strategies to the Perfect Surgical Scar
  5. Update on Drugs and Drugs News